• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager

    4/8/24 12:44:00 PM ET
    $DOW
    $PFE
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOW alert in real time by email

    HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager.

    Scott Barnum, Director of Manufacturing

    Mr. Barnum will oversee the process management, quality, and operations of ALTIVIA's Specialty and Oxide Chemicals' units. Mr. Hale will lead the development and management of ALTIVIA's Corporate Engineering Department.

    "We look forward to welcoming both Scott and Dean as ALTIVIA furthers its investment in growth, sustainability, and world-class operating performance," said Michael Jusbasche, ALTIVIA's Chief Executive Officer. "Their proven leadership and experience in the chemicals industry will fuel ALTIVIA's growth."

    Scott Barnum

    Mr. Barnum has 30 years of experience in the chemicals industry, including phosgenation, chlorination, sulfonation, and esterification processes. Prior to joining ALTIVIA, Mr. Barnum served as the Director of Manufacturing at Niacet Corporation, a division of Kerry Group, plc (OTC Markets KRYAY), an industry-leading manufacturer in food feed, and pharmaceutical additives. Mr. Barnum served as board member of the Buffalo Niagara Manufacturing Alliance, representing 194 member companies.

    During his career, Mr. Barnum has been recognized for his contributions to environmental, safety, and health management. Mr. Barnum holds a Bachelor of Science in Chemical Engineering from The State University of New York.

    Dean Hale

    Mr. Hale has spent the last 33 years in various engineering capacities in the chemicals industry, focused on process development, implementation, and optimization. He brings a breadth of industry experience in applications including petrochemicals, semiconductor chemicals, pharmaceuticals, and food additives. Prior to joining ALTIVIA, he most recently served as the Engineering Manager for Niacet Corporation, a division of Kerry Group, plc (OTC Markets: KRYAY), and has held various engineering and project management roles for DOW (NYSE:DOW) and Pfizer (NYSE:PFE).

    Mr. Hale has been a recipient of the Pfizer Innovation Award and the Teamwork Award, and Pharmacia's Outstanding Performance Recognition Award. Mr. Hale holds a Bachelor of Science in Chemical Engineering from Michigan State University and is certified as a Project Management Professional.

    Mr. Barnum's and Mr. Hale's leadership were instrumental in Niacet's winning the American Chemistry Council's (ACC) Company of the Year Award for outstanding environmental, safety, health, and security performance.

    About ALTIVIA

    Headquartered in Houston, Texas, privately held ALTIVIA was founded in 1986 and today operates four petrochemical and specialty chemical manufacturing facilities in Texas, Ohio, and West Virginia.

    • ALTIVIA Petrochemicals, with facilities in Haverhill, Ohio, is the third largest merchant producer of Phenol, Acetone, and alpha-methyl-styrene in the Americas.
    • ALTIVIA Specialty Chemicals, the largest producer of Phosgene derivative intermediates in the Americas, including chloroformates and acid chlorides, serving the pharmaceutical, organic peroxide, and agricultural markets from its operations in LaPorte, Texas.
    • ALTIVIA Ketones & Additives, a global leader and producer of ketones and carbinols at its facilities in Institute, West Virginia. This business was acquired from The Dow Chemical Company in 2019, and it serves the coatings, industrial and automotive lubricants, and adhesives industries.
    • ALTIVIA Oxide Chemicals specializes in custom production of various chemical intermediates serving surfactant, lubricant, and fuel additives markets. The production facility in Crosby, Texas, includes 31 reactors and distillation trains with ethoxylation, propoxylation and a range of organic reaction capabilities.

    For more information contact:

    Kelly Kimberly

    +1.713.822.7538

    [email protected] 

    Dean Hale, Corporate Engineering Manager

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/altivia-appoints-scott-barnum-as-director-of-manufacturing-and-dean-hale-as-corporate-engineering-manager-302110654.html

    SOURCE ALTIVIA

    Get the next $DOW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOW
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    3/2/2026$35.00Hold → Buy
    Argus
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Pfizer Inc.
    $PFE
    1/7/2026$25.00Neutral
    UBS
    Pfizer Inc.
    $PFE
    12/2/2025$26.00Neutral
    Citigroup
    Pfizer Inc.
    $PFE
    11/13/2025$30.00Sector Outperform
    Scotiabank
    Dow Inc.
    $DOW
    8/14/2025$25.00Underperform → Neutral
    BofA Securities
    More analyst ratings

    $DOW
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOW
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dial Debra L. bought $26,197 worth of shares (675 units at $38.81) (SEC Form 4)

    4 - DOW INC. (0001751788) (Issuer)

    2/11/25 4:15:26 PM ET
    $DOW
    Major Chemicals
    Industrials

    Director Banister Gaurdie E. Jr. bought $299,932 worth of shares (7,339 units at $40.87) (SEC Form 4)

    4 - DOW INC. (0001751788) (Issuer)

    12/17/24 4:59:47 PM ET
    $DOW
    Major Chemicals
    Industrials

    $DOW
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

    LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current

    3/2/26 5:31:00 PM ET
    $BOLD
    $CMPX
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Commercial Physical & Biological Resarch

    ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

    VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demonstrate improved potency and an enhanced resistance profile versus bictegravir VH499 demonstrates good tolerability, supporting twice-yearly dosing intervals ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase strand transfer inhibitor (INSTI) in development for HIV.1 Results show a single-dose injection could maintain drug levels for up

    2/25/26 2:00:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

    94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir These phase IIb results reinforce lotivibart's ultra long-acting potential, with the trial progressing to evaluate a twice-yearly intravenous dosing interval ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults living with HIV on stable therapy, a regimen of lotivibart (N6LS), a broadly neutralising antibody, administered every four months combined w

    2/25/26 2:00:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOW
    $PFE
    SEC Filings

    View All

    SEC Form DEF 14A filed by Dow Inc.

    DEF 14A - DOW INC. (0001751788) (Filer)

    2/27/26 4:08:37 PM ET
    $DOW
    Major Chemicals
    Industrials

    SEC Form DEFA14A filed by Dow Inc.

    DEFA14A - DOW INC. (0001751788) (Filer)

    2/27/26 4:10:38 PM ET
    $DOW
    Major Chemicals
    Industrials

    SEC Form DEFA14A filed by Dow Inc.

    DEFA14A - DOW INC. (0001751788) (Filer)

    2/27/26 4:09:53 PM ET
    $DOW
    Major Chemicals
    Industrials

    $DOW
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pfizer upgraded by Argus with a new price target

    Argus upgraded Pfizer from Hold to Buy and set a new price target of $35.00

    3/2/26 8:00:47 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Pfizer with a new price target

    RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    2/25/26 7:53:28 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOW
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Tech & Sustainability Argenton Andre returned $23,651 worth of shares to the company (791 units at $29.90), decreasing direct ownership by 1% to 50,919 units (SEC Form 4)

    4 - DOW INC. (0001751788) (Issuer)

    3/2/26 5:17:03 PM ET
    $DOW
    Major Chemicals
    Industrials

    General Counsel / Secretary Wilson Amy E returned $111,168 worth of shares to the company (3,718 units at $29.90), decreasing direct ownership by 3% to 113,133 units (SEC Form 4)

    4 - DOW INC. (0001751788) (Issuer)

    3/2/26 5:16:53 PM ET
    $DOW
    Major Chemicals
    Industrials

    President, Pkg & Spec Plastics Cleason Keith returned $20,511 worth of shares to the company (686 units at $29.90), decreasing direct ownership by 1% to 57,052 units (SEC Form 4)

    4 - DOW INC. (0001751788) (Issuer)

    3/2/26 5:16:41 PM ET
    $DOW
    Major Chemicals
    Industrials

    $DOW
    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    Valtris Specialty Chemicals Announces New Chief Executive Officer

    Industry veteran Mike McGaugh appointed Valtris Specialty Chemicals ("Valtris"), a leading global manufacturer of a comprehensive portfolio of specialty additives, announced today the appointment of Mike McGaugh as the company's new Chief Executive Officer. Mr. McGaugh has assumed the role held by former CEO, Simon Medley, who will be retiring as part of this transition but will continue to advise the company. Valtris is a portfolio company of SK Capital. "We are thrilled to welcome Mike, an industry veteran with a proven track record in the chemical and materials industries," said Jack Norris, a Managing Director of SK Capital. "Mike's decades of demonstrated leadership experience and

    1/13/26 6:30:00 AM ET
    $DOW
    $MYE
    Major Chemicals
    Industrials
    Plastic Products

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOW
    $PFE
    Financials

    Live finance-specific insights

    View All

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough

    2/23/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dow declares quarterly dividend of 35 cents per share

    MIDLAND, Mich., Feb. 12, 2026 /PRNewswire/ -- Dow (NYSE:DOW) has declared a dividend of 35 cents per share, payable March 13, 2026, to shareholders of record on February 27, 2026. This marks the 458th consecutive dividend paid by the Company or its affiliates since 1912. About DowDow (NYSE:DOW) is one of the world's leading materials science companies, serving customers in high-growth markets such as packaging, infrastructure, mobility and consumer applications. Our global breadth, asset integration and scale, customer-focused innovation and leading business positions enable u

    2/12/26 4:15:00 PM ET
    $DOW
    Major Chemicals
    Industrials

    Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

    Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc

    2/3/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOW
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dow Inc.

    SC 13G/A - DOW INC. (0001751788) (Subject)

    11/12/24 2:25:16 PM ET
    $DOW
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Dow Inc.

    SC 13G/A - DOW INC. (0001751788) (Subject)

    11/4/24 11:51:32 AM ET
    $DOW
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Dow Inc.

    SC 13G/A - DOW INC. (0001751788) (Subject)

    10/17/24 12:57:12 PM ET
    $DOW
    Major Chemicals
    Industrials